Zobrazeno 1 - 10
of 31
pro vyhledávání: '"D. Ego"'
Autor:
S. Afanasiev, G. Agakishiev, E. Aleksandrov, I. Aleksandrov, P. Alekseev, K. Alishina, E. Atkin, T. Aushev, V. Babkin, N. Balashov, A. Baranov, D. Baranov, N. Baranova, N. Barbashina, M. Baznat, S. Bazylev, M. Belov, D. Blau, G. Bogdanova, D. Bogoslovsky, A. Bolozdynya, E. Boos, M. Buryakov, S. Buzin, A. Chebotov, J. Chen, D. Dementev, A. Dmitriev, D. Dryablov, A. Dryuk, P. Dulov, D. Egorov, V. Elsha, A. Fediunin, I. Filippov, I. Filozova, D. Finogeev, I. Gabdrakhmanov, A. Galavanov, O. Gavrischuk, K. Gertsenberger, V. Golovatyuk, M. Golubeva, F. Guber, A. Iusupova, A. Ivashkin, A. Izvestnyy, V. Kabadzhov, M. Kapishin, I. Kapitonov, V. Karjavin, D. Karmanov, N. Karpushkin, R. Kattabekov, V. Kekelidze, S. Khabarov, P. Kharlamov, A. Khukhaeva, A. Khvorostukhin, Y. Kiryushin, P. Klimai, D. Klimansky, V. Kolesnikov, A. Kolozhvari, Y. Kopylov, M. Korolev, L. Kovachev, I. Kovalev, Y. Kovalev, I. Kozlov, V. Kozlov, I. Kudryashov, S. Kuklin, E. Kulish, A. Kurganov, A. Kuznetsov, E. Ladygin, D. Lanskoy, N. Lashmanov, V. Lenivenko, R. Lednický, V. Leontiev, E. Litvinenko, Y.-G. Ma, A. Makankin, A. Makhnev, A. Malakhov, A. Martemianov, E. Martovitsky, K. Mashitsin, M. Merkin, S. Merts, A. Morozov, S. Morozov, Y. Murin, G. Musulmanbekov, A. Myasnikov, R. Nagdasev, E. Nekrasowa, S. Nemnyugin, D. Nikitin, S. Novozhilov, V. Palchik, I. Pelevanyuk, D. Peresunko, O. Petukhov, Y. Petukhov, S. Piyadin, M. Platonova, V. Plotnikov, D. Podgainy, V. Rogov, I. Rufanov, P. Rukoyatkin, M. Rumyantsev, D. Sakulin, S. Sergeev, A. Sheremetev, A. Sheremeteva, A. Shchipunov, M. Shitenkov, M. Shopova, V. Shumikhin, A. Shutov, V. Shutov, I. Slepnev, V. Slepnev, I. Slepov, A. Solomin, A. Sorin, V. Sosnovtsev, V. Spaskov, A. Stavinskiy, Yu. Stepanenko, E. Streletskaya, O. Streltsova, M. Strikhanov, N. Sukhov, D. Suvarieva, G. Taer, N. Tarasov, O. Tarasov, P. Teremkov, A. Terletsky, O. Teryaev, V. Tcholakov, V. Tikhomirov, A. Timoshenko, N. Topilin, T. Tretyakova, V. Tskhay, E. Tsvetkov, I. Tyapkin, V. Vasendina, V. Velichkov, V. Volkov, A. Voronin, N. Voytishin, V. Yurevich, I. Yumatova, N. Zamiatin, M. Zavertyaev, S. Zhang, E. Zherebtsova, V. Zhezher, N. Zhigareva, A. Zinchenko, A. Zubankov, E. Zubarev, M. Zuev
Publikováno v:
Journal of High Energy Physics, Vol 2023, Iss 7, Pp 1-27 (2023)
Abstract First physics results of the BM@N experiment at the Nuclotron/NICA complex are presented on π + and K + meson production in interactions of an argon beam with fixed targets of C, Al, Cu, Sn and Pb at 3.2 A GeV. Transverse momentum distribut
Externí odkaz:
https://doaj.org/article/6429cd74fcba42a894dfe5a12aafe052
Autor:
P. Liubov, D. Egorova
Publikováno v:
European Psychiatry, Vol 66, Pp S234-S234 (2023)
Introduction One of the most common mental disorders in the elderly is depression. Because of the high frequency of side effects of pharmacotherapy and the comorbid medical illnesses, there are not many ways to treat it. Non-drug therapies, such as r
Externí odkaz:
https://doaj.org/article/cb9f3e00a4c047b3be4171a7a4403f88
Publikováno v:
Experimental cell research. 312(12)
The level of integrin alpha(v)beta3 and its ligand osteopontin (OPN) has been directly correlated to tumorigenicity of melanoma and other cancer cells. We have previously shown an increase in pp(60c-Src) kinase activity associated with integrin alpha
Publikováno v:
Journal of neural transmission. Supplementum. 41
In vitro and ex-vivo studies show that befloxatone, a new oxazolidinone derivative, is a potent, reversible, competitive and specific MAO-A inhibitor (KiA from 1.9 to 3.6 nM and KiB/KiA ratio between 100 and 400, in the Rat and in Man, depending on t
Publikováno v:
Amine Oxidases: Function and Dysfunction ISBN: 9783211825211
In vitro and ex-vivo studies show that befloxatone, a new oxazolidinone derivative, is a potent, reversible, competitive and specific MAO-A inhibitor (KiA from 1.9 to 3.6 nM and KiB/KiA ratio between 100 and 400, in the Rat and in Man, depending on t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a217261cc2b39f16352d08f81ffc5d0
https://doi.org/10.1007/978-3-7091-9324-2_45
https://doi.org/10.1007/978-3-7091-9324-2_45
Autor:
C. Derks, O. Curet, M. Ansseau, D. Ego, I. Cieren-Puiseux, J. Wauthy, A. Thiola, P. Caillé, F. X. Jarreau, V. Rovei
Publikováno v:
Clinical Neuropharmacology. 15:328B
Publikováno v:
Clinical Neuropharmacology. 15:422B
Autor:
C. Derks, P. Caillé, D. Rovei, I. Cieren-Puiseux, F. X. Jarreau, J. Wauthy, M. Ansseau, D. Ego
Publikováno v:
Clinical Neuropharmacology. 15:328B
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 23:553-564
Ethyl 2-acetylamino-2-carbethoxy-4-cyano-3-butene oate : 3 was prepared by condensation of trans-1-bromo-2-cyanoethylene : 2 with ethyl sodio acetamidomalonate. 3 was catalytically reduced with tritium followed by hydrolysis giving rise to (3,4,5,5-3
Publikováno v:
European journal of clinical pharmacology. 33(3)
The pharmacokinetics of bendazac and its major metabolite, 5-hydroxybendazac, have been investigated in 15 patients with moderate to severe renal insufficiency and renal failure following a single oral dose of 500 mg bendazac-lysine. The pharmacokine